Abstract PS5-07-04: NRG-BR009: A phase III trial evaluating addition of adjuvant chemotherapy to Ovarian Function Suppression + Endocrine Therapy in premenopausal women with pN0-1, HR+/HER2- breast cancer and recurrence score ≤25 (OFSET)
Year: 2026
Type: conference-abstract
Source: Clinical Cancer Research
Institutions: Georgetown University Medical Center, Georgetown Lombardi Comprehensive Cancer Center, MedStar Health, University of Pittsburgh, NRG Oncology, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center, University of Michigan, Michigan Medicine, Vanderbilt University Medical Center, The University of Kansas Cancer Center, University of Kansas Medical Center, Abramson Cancer Center, University of Pennsylvania, Mayo Clinic, Mayo Clinic Comprehensive Cancer Center (Minnesota), West Cancer Center, NSABP Foundation, AdventHealth Orlando, AdventHealth
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W7129735716